Abstract
Since the first human catheterization performed by Forssman in 1929 angioplasty equipment and medical therapies have undergone considerable evolution and technical improvement allowing interventionalists to perform more complex procedures and solving most of the percutaneous limitations. While percutaneous coronary intervention (PCI) has dramatically changed the outcome in the Acute Coronary Syndrome (ACS) setting, its role in the treatment of chronic stable angina is still debated. Stable coronary artery disease (SCAD) is a major public health issue and its prevalence is still increasing in the industrialized world. The correct treatment sees a multi-strategy approach aimed to a relief of symptoms, prevention of future cardiac events and survival improvement. In so forth, treatment strategies include optimal medical therapy (OMT) alone or combined with percutaneous or surgical coronary revascularization. Despite this, angina remains poorly controlled in the vast majority of CAD patients. Traditional agents such Beta-blockers or Calcium channel blockers or short and long acting nitrates have been used as first-line anti-anginal therapy for several years. Nowadays newer and more effective drugs usually used on top of older medical treatment have become available.
Keywords: Acute coronary syndrome, coronary revascularization, new anti-anginal drugs, percutaneous coronary intervention, stable angina, unstable angina.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Old and New Drugs for Treatment of Stable Angina: New Anti-Anginal Drugs and Coronary Revascularization
Volume: 13 Issue: 1
Author(s): Gioel Gabrio Secco, Rosario Parisi, Francesca Mirabella, Andrea Rognoni, Alessandro Lupi, Giuseppe De Luca, Paolo Nicola Marino, Rossella Fattori, Alberto Cremonesi and Fausto Castriota
Affiliation:
Keywords: Acute coronary syndrome, coronary revascularization, new anti-anginal drugs, percutaneous coronary intervention, stable angina, unstable angina.
Abstract: Since the first human catheterization performed by Forssman in 1929 angioplasty equipment and medical therapies have undergone considerable evolution and technical improvement allowing interventionalists to perform more complex procedures and solving most of the percutaneous limitations. While percutaneous coronary intervention (PCI) has dramatically changed the outcome in the Acute Coronary Syndrome (ACS) setting, its role in the treatment of chronic stable angina is still debated. Stable coronary artery disease (SCAD) is a major public health issue and its prevalence is still increasing in the industrialized world. The correct treatment sees a multi-strategy approach aimed to a relief of symptoms, prevention of future cardiac events and survival improvement. In so forth, treatment strategies include optimal medical therapy (OMT) alone or combined with percutaneous or surgical coronary revascularization. Despite this, angina remains poorly controlled in the vast majority of CAD patients. Traditional agents such Beta-blockers or Calcium channel blockers or short and long acting nitrates have been used as first-line anti-anginal therapy for several years. Nowadays newer and more effective drugs usually used on top of older medical treatment have become available.
Export Options
About this article
Cite this article as:
Secco Gabrio Gioel, Parisi Rosario, Mirabella Francesca, Rognoni Andrea, Lupi Alessandro, De Luca Giuseppe, Marino Nicola Paolo, Fattori Rossella, Cremonesi Alberto and Castriota Fausto, Old and New Drugs for Treatment of Stable Angina: New Anti-Anginal Drugs and Coronary Revascularization, Cardiovascular & Hematological Agents in Medicinal Chemistry 2015; 13 (1) . https://dx.doi.org/10.2174/1871525713666141219114240
DOI https://dx.doi.org/10.2174/1871525713666141219114240 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Smoking and Atherosclerosis: Mechanisms of Disease and New Therapeutic Approaches
Current Medicinal Chemistry Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Pathogenesis and Treatment Options
Current Vascular Pharmacology Thrombin-Activatable Fibrinolysis Inhibitor
Current Medicinal Chemistry Obesity-Associated Hypertension in Childhood: A New Epidemic Problem
Current Hypertension Reviews Isolation, Structural Determination, and Evaluation of the Biological Activity of 20(S)-25-methoxyl-dammarane-3β, 12β, 20-triol [20(S)-25-OCH3-PPD], a Novel Natural Product from Panax notoginseng
Medicinal Chemistry Cardiovascular Disease Risk Among the Poor and Homeless – What We Know So Far
Current Cardiology Reviews Cancer Treatment-Induced Cardiotoxicity: a Cardiac Stem Cell Disease?
Cardiovascular & Hematological Agents in Medicinal Chemistry Prevalence of Obesity, Hypertension, Diabetes, and Metabolic Syndrome and Its Cardiovascular Complications
Current Hypertension Reviews Molecular and Biochemical Changes of the Cardiovascular System due to Smoking Exposure
Current Pharmaceutical Design Pollen Diversity, Antiradical and Antibacterial Activity and Phenolic Contents of some Polish Honeys
Current Nutrition & Food Science Pharmacological Therapies for Pediatric and Neonatal ALI/ARDS: An Evidence-Based Review
Current Drug Targets Oligonucleotide Aptamers for Glioma Targeting: An Update
Central Nervous System Agents in Medicinal Chemistry Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload
Infectious Disorders - Drug Targets MRI Contrast Agents: Current Status and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Preface:
Current Topics in Medicinal Chemistry The role of interleukin 35 in atherosclerosis
Current Pharmaceutical Design Is the Therapeutic Potential of Stem Cells for Myocardial Regeneration Limited by Proarrhythmic Effects?
Current Cardiology Reviews New Frontiers in Regenerative Medicine in Cardiology: The Potential of Wharton’s Jelly Mesenchymal Stem Cells
Current Stem Cell Research & Therapy The Innovations in Pulmonary Hypertension Pathophysiology and Treatment: What are our Options!
Current Respiratory Medicine Reviews Sudden Unexpected Death in Infancy and the Dilemma of Defining the Sudden Infant Death Syndrome
Current Pediatric Reviews